You just read:

Peptide Logic Awarded A $ 2.9 Million SBIR Phase II Grant To Develop Peripherally-Restricted And Long-Acting Kappa-Opioid Receptor (LA-KOR) Agonists For Moderate-To-Severe Pain

News provided by

Peptide Logic

Aug 15, 2018, 11:00 ET